INVACARE CORPORATION (NYSE:IVC) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
INVACARE CORPORATION (NYSE:IVC) Files An 8-K Regulation FD Disclosure
On March 23, 2020, Invacare Corporation (the “Company”) issued a press release providing a business update regarding the impact of COVID-19 on the Company. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
INVACARE CORP Exhibit
EX-99.1 2 exhibitmarch2020.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 NEWS RELEASECONTACT:Lois Lee [email protected] 440-329-6435Invacare Provides COVID-19 Business UpdateElyria,…
To view the full exhibit click
EX-99.1 2 exhibitmarch2020.htm EXHIBIT 99.1 Exhibit Exhibit 99.1 NEWS RELEASECONTACT:Lois Lee [email protected] 440-329-6435Invacare Provides COVID-19 Business UpdateElyria,…
To view the full exhibit click
hereAbout INVACARE CORPORATION (NYSE:IVC)
Invacare Corporation is a manufacturer and distributor for medical equipment used in non-acute care settings. The Company’s geographical segments are Europe; North America, which includes North America/Home Medical Equipment (North America/HME) and Institutional Products Group (IPG) segments, and Asia/Pacific. The Company manufactures and distributes three product categories: mobility and seating, lifestyle and respiratory therapy. It provides medical device solutions for congenital (cerebral palsy, muscular dystrophy and spina bifida), acquired (stroke, spinal cord injury, traumatic brain injury, post-acute recovery and pressure ulcers) and degenerative (amyotrophic lateral sclerosis, multiple sclerosis, chronic obstructive pulmonary disease (COPD), elderly and bariatric) ailments. The Company sells its products to home medical equipment providers with retail and e-commerce channels, residential living operators, distributors and government health services.
